Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
461. |
ECCT/24/04/05 | Phase III Vitiligo Study A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB- UVB Light Alone in the Treatment of Vitiligo |
Principal Investigator(s) 1. Dr. Hannah Wanyika Wanyika Site(s) in Kenya Kenyatta National Hospital - |
View |
462. |
ECCT/22/01/01 | ASTEFANIA A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
463. |
ECCT/19/06/03 | Evaluation of the RTS,S vaccine implementation in Kenya (MVPE) An evaluation of the cluster-randomised pilot implementation of the RTS,S/AS01 malaria vaccine through routine health systems in western Kenya |
Principal Investigator(s) 1. Aaron Samuels Samuels Site(s) in Kenya 1. Bungoma County (Bung\'oma county) 2. Busia County (Busia county) 3. Homa Bay (Homa Bay county) 4. Kakamega County (Kakamega county) 5. Kisumu County (Kisumu county) 6. Migori County (Migori county) 7. Siaya County (Siaya county) 8. Vihiga County (Vihiga county) |
View |
464. |
ECCT/19/07/01 | IMPROVE-2 chemoprevention with monthly IPTp with dihydroartemisinin-piperaquine for malaria in HIV-infected pregnant participants on daily cotrimoxazole in Kenya and Malawi: a multi-centre placebo-controlled trial(IMPROVE-2). |
Principal Investigator(s) 1. Hellen Cherono Barsosio 2. Simon Kariuki Site(s) in Kenya 1. Ahero Sub-County Hospital (Kisumu county) 2. Rabuor Sub-County Hospital (Kisumu county) 3. Akala Sub-County Hospital (Siaya county) |
View |
465. |
ECCT/22/05/02 | BREATHER Plus A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |